

# Massimo Martino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4304808/publications.pdf>

Version: 2024-02-01

157  
papers

1,948  
citations

318942

23  
h-index

445137

33  
g-index

160  
all docs

160  
docs citations

160  
times ranked

2781  
citing authors

#	ARTICLE	IF	CITATIONS
1	Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. <i>Supportive Care in Cancer</i> , 2022, 30, 585-591.	1.0	4
2	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	1.4	1
3	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	0.6	13
4	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. <i>Bone Marrow Transplantation</i> , 2022, 57, 384-390.	1.3	10
5	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	1.3	16
6	Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. <i>Bone Marrow Transplantation</i> , 2022, 57, 949-958.	1.3	7
7	Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
8	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	0.8	6
9	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	1.3	7
10	The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e402-e409.	0.2	4
11	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 1272-1280.	1.3	18
12	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	0.6	4
13	An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1025-1034.	1.4	4
14	A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2150.	1.8	60
15	Chemotherapy-based regimens in multiple myeloma in 2020. <i>Panminerva Medica</i> , 2021, 63, 7-12.	0.2	10
16	Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. , 2021, 9, e002026.		11
17	Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 244.e1-244.e8.	0.6	14
18	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. <i>Annals of Hematology</i> , 2021, 100, 1743-1753.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transplantation, 2021, 56, 1842-1849.	1.3	4
20	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). Bone Marrow Transplantation, 2021, 56, 2272-2275.	1.3	12
21	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. International Journal of Hematology, 2021, 114, 228-234.	0.7	16
22	CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers, 2021, 13, 2639.	1.7	17
23	Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Drug Design, Development and Therapy, 2021, Volume 15, 2969-2978.	2.0	9
24	The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1665-1679.	0.7	1
25	The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 918.e1-918.e9.	0.6	3
26	Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. Frontiers in Oncology, 2021, 11, 740079.	1.3	19
27	Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking?. Panminerva Medica, 2021, 62, 234-243.	0.2	3
28	Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. Bone Marrow Transplantation, 2021, , .	1.3	0
29	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Biology of Blood and Marrow Transplantation, 2020, 26, 936-942.	2.0	15
30	A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. Annals of Hematology, 2020, 99, 331-341.	0.8	4
31	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. Expert Opinion on Pharmacotherapy, 2020, 21, 29-38.	0.9	3
32	Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. Transfusion and Apheresis Science, 2020, 59, 102911.	0.5	0
33	Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. Frontiers in Oncology, 2020, 10, 592487.	1.3	7
34	Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost. Leukemia Research Reports, 2020, 14, 100227.	0.2	1
35	Impact of donor age and kinship on clinical outcomes after T-cell replete haploidentical transplantation with PT-Cy. Blood Advances, 2020, 4, 3900-3912.	2.5	30
36	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplantation, 2020, 55, 2077-2086.	1.3	5

#	ARTICLE	IF	CITATIONS
37	Manipulation, and cryopreservation of autologous peripheral blood stem cell products in Italy: A survey by GITMO, SIDEM and GIIMA societies. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102753.	0.5	12
38	A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. <i>Transfusion and Apheresis Science</i> , 2020, 59, 102819.	0.5	6
39	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibodyâ€”Beigelomab. <i>Bone Marrow Transplantation</i> , 2020, 55, 1580-1587.	1.3	21
40	Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogeneic Stem Cell Transplant and Dasatinib: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 967.	1.3	1
41	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	1.7	17
42	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2766-2775.	3.3	30
43	Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT. <i>Blood</i> , 2020, 136, 9-9.	0.6	0
44	A Patient with Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia and Multiple Myeloma. <i>Blood</i> , 2020, 136, 37-37.	0.6	1
45	Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hrsplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
46	The use of ibrutinib before and after allogeneic stem cell transplantation. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 171-180.	0.5	1
47	Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. <i>Expert Review of Hematology</i> , 2019, 12, 665-684.	1.0	13
48	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3566-3573.	2.0	17
49	Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1586-1591.	2.0	7
50	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT.. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S242-S243.	2.0	2
51	Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. <i>Blood Advances</i> , 2019, 3, 1197-1210.	2.5	76
52	Bone Marrow Versus Mobilized Peripheral Blood Stem Cells for Non T Depleted Haploidentical Transplantations with Post Transplantation Cyclophosphamide in Acute Lymphoblastic Leukemia: On Behalf of the ALWP of the EBMT. <i>Blood</i> , 2019, 134, 589-589.	0.6	0
53	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. <i>Bone Marrow Transplantation</i> , 2018, 53, 461-473.	1.3	28
54	Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 42-48.	0.6	12

#	ARTICLE	IF	CITATIONS
55	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 608-613.	2.0	19
56	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018, 132, 4586-4586.	0.6	1
57	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. <i>Blood</i> , 2018, 132, 2023-2023.	0.6	0
58	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity score weighted multicenter approach. <i>American Journal of Hematology</i> , 2017, 92, E557-E559.	2.0	10
59	Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 506-512.	0.2	16
60	Basal CD34 + Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony-Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1215-1220.	2.0	14
61	Venetoclax for the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1307-1316.	1.9	48
62	Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 875-887.	0.5	3
63	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	0.9	3
64	Chemotherapy and Cardiotoxicity in Hematologic Malignancies. <i>Current Cancer Drug Targets</i> , 2017, 17, 311-324.	0.8	8
65	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1032-1040.	1.3	26
66	A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1197-1203.	1.3	28
67	Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1361-1372.	1.4	4
68	The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 26.	6.9	9
69	Sorafenib for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 743-749.	1.9	10
70	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
71	The role of tandem stem cell transplantation for multiple myeloma patients. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 515-534.	1.4	10
72	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 2016, 51, 384-390.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 347-364.	1.4	4
74	Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 969-972.	0.6	1
75	Basal CD34+ Cell Count Predicts Peripheral Blood Hematopoietic Progenitor Cells Mobilization in Healthy Donors after Administration of G-CSF. <i>Blood</i> , 2016, 128, 3380-3380.	0.6	1
76	Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control. <i>Transfusion</i> , 2015, 55, 2032-2038.	0.8	6
77	Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. <i>Journal of Immunology Research</i> , 2015, 2015, 1-11.	0.9	12
78	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 689-702.	1.1	10
79	Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 149-154.	1.4	9
80	Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 195-211.	1.4	2
81	Smoldering multiple myeloma: to treat or not to treat. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 785-790.	0.9	3
82	Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. <i>Cytotherapy</i> , 2015, 17, 1485-1493.	0.3	17
83	Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 881-888.	2.0	14
84	High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for De Novo Multiple Myeloma Patients: A Phase II Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1932-1938.	2.0	20
85	Plerixafor: what we still have to learn. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 143-147.	1.4	13
86	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 857-872.	1.4	18
87	High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 70-75.	0.9	13
88	A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm prospective, non-randomized study. <i>Leukemia and Lymphoma</i> , 2015, 56, 801-804.	0.6	17
89	Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. <i>Tumor Biology</i> , 2015, 36, 6653-6665.	0.8	38
90	High-dose chemotherapy for germ cell tumors: do we have a model?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 33-44.	1.4	15



#	ARTICLE	IF	CITATIONS
91	Results and Cost Effectiveness of "on-Demand" Plerixafor Added to Chemotherapy and Granulocyte Colony-Stimulating Factor for Peripheral Blood Stem Cell Mobilization in Multiple Myeloma. <i>Blood</i> , 2015, 126, 4305-4305.	0.6	0
92	Fast and Non-Invasive Identification of Tumorigenic-Proliferative Biomarker in Myeloproliferative and Lymphoproliferative Disorders. <i>Blood</i> , 2015, 126, 5305-5305.	0.6	0
93	A Phase 2 Study of Bendamustine Plus Melphalan Conditioning for Second Autologous Stem Cell Transplantation in "De-Novo" Multiple Myeloma Patients in a Tandem Transplant Strategy. <i>Blood</i> , 2015, 126, 3197-3197.	0.6	0
94	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
95	Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 757-772.	1.4	15
96	Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1315-1320.	0.9	6
97	Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 501-506.	2.0	7
98	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
99	Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. <i>Transfusion</i> , 2014, 54, 2028-2033.	0.8	27
100	Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 493-500.	0.2	7
101	Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. <i>British Journal of Haematology</i> , 2014, 164, 113-123.	1.2	55
102	Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 148-154.	0.2	13
103	Plerixafor with biosimilar granulocyte colony-stimulating factor (G-CSF): effective strategy in peripheral blood stem cell (PBSC) mobilization in poor mobilizers. <i>Transfusion and Apheresis Science</i> , 2014, 50, S20-S21.	0.5	0
104	Homozygosity for Killer Immunoglobulin-like Receptor (KIR) Haplotype a1s Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma. <i>Blood</i> , 2014, 124, 133-133.	0.6	1
105	Bendamustine Plus Melphalan As Conditioning Regimen for Second Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Single Centre Experience. <i>Blood</i> , 2014, 124, 2516-2516.	0.6	3
106	Safety of Peripheral Hematopoietic Stem Cell Mobilization with Lenograstim in Allogeneic Healthy Donors ≥ 50 Years Old: A Single-Centre Experience. <i>Blood</i> , 2014, 124, 3844-3844.	0.6	0
107	Biosimilar Compared with Originator Filgrastim for Autologous Stems CELL Mobilisation: A Prospective-Historical Control Study in Multiple Myeloma REAL-Life Setting. <i>Blood</i> , 2014, 124, 5825-5825.	0.6	0
108	An old drug with a new future: bendamustine in multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2263-2280.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 2013, 13, 1013-1027.	1.4	2
110	Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opinion on Investigational Drugs, 2013, 22, 619-634.	1.9	17
111	Are there still reasons to believe that high-dose chemotherapy has a role in breast cancer management?. Bone Marrow Transplantation, 2013, 48, 305-305.	1.3	2
112	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplantation, 2013, 48, 414-418.	1.3	16
113	Diagnostic approaches for identifying acute graft-versus-host disease: what comes next?. Immunotherapy, 2013, 5, 553-556.	1.0	0
114	Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents. Current Cancer Drug Targets, 2013, 13, 661-669.	0.8	16
115	Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. Blood Transfusion, 2013, 11, 94-101.	0.3	13
116	Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Bone Marrow Transplantation, 2012, 47, 308-310.	1.3	5
117	Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opinion on Biological Therapy, 2012, 12, 1505-1515.	1.4	14
118	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opinion on Biological Therapy, 2012, 12, 1449-1462.	1.4	18
119	Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. Expert Opinion on Biological Therapy, 2012, 12, 1017-1030.	1.4	9
120	Internal Iliac Artery Perforation following Bone Marrow Aspiration in a Patient with No Previously Identified Risk Factors: A Case Report and Review of the Literature. Acta Haematologica, 2012, 127, 23-25.	0.7	4
121	A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. Haematologica, 2012, 97, 1532-1538.	1.7	8
122	Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma. Biology of Blood and Marrow Transplantation, 2012, 18, 241-249.	2.0	69
123	Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear?. Expert Opinion on Biological Therapy, 2012, 12, 609-621.	1.4	20
124	The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfusion, 2012, 10, 174-80.	0.3	38
125	CD34+ mobilization and pbsc apheretic harvest in multiple myeloma patients at first mobilization attempt: variability in results among different centers. Drugs and Cell Therapies in Hematology, 2012, 1, 91.	0.1	1
126	Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Leukemia and Lymphoma, 2011, 52, 2010-2011.	0.6	2



#	ARTICLE	IF	CITATIONS
127	Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. <i>Bone Marrow Transplantation</i> , 2009, 44, 163-168.	1.3	35
128	Utility of the Clinical Practice of Administering Thrombophilic Screening and Antithrombotic Prophylaxis with Low-Molecular-Weight Heparin to Healthy Donors Treated with G-Csf for Mobilization of Peripheral Blood Stem Cells. <i>Tumori</i> , 2007, 93, 155-159.	0.6	2
129	Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. <i>European Journal of Haematology</i> , 2007, 78, 35-40.	1.1	16
130	Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells. <i>Tumori</i> , 2007, 93, 155-9.	0.6	2
131	Wernicke's encephalopathy after allogeneic stem cell transplantation. <i>Tumori</i> , 2007, 93, 207-9.	0.6	1
132	Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. <i>British Journal of Cancer</i> , 2006, 94, 1016-1020.	2.9	39
133	Different $\beta_2\mu$ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. <i>Leukemia Research</i> , 2006, 30, 529-535.	0.4	14
134	Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. <i>European Journal of Haematology</i> , 2006, 77, 410-415.	1.1	38
135	Predictive factors that affect the mobilization of CD34+cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). <i>Journal of Clinical Apheresis</i> , 2006, 21, 169-175.	0.7	33
136	High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. <i>American Journal of Hematology</i> , 2006, 81, 973-978.	2.0	7
137	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>Leukemia Research</i> , 2005, 29, 961-966.	0.4	56
138	'In vivo' time course of plasma myeloperoxidase levels after granulocyte colony-stimulating factor-induced stem cell mobilization. <i>Transfusion Medicine</i> , 2005, 15, 425-428.	0.5	5
139	Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. <i>Transfusion Medicine</i> , 2005, 15, 323-328.	0.5	13
140	Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. <i>Journal of Clinical Apheresis</i> , 2005, 20, 129-136.	0.7	26
141	Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. <i>Supportive Care in Cancer</i> , 2005, 13, 182-187.	1.0	6
142	Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization. <i>Transfusion and Apheresis Science</i> , 2005, 33, 141-146.	0.5	4
143	Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. <i>Transplant Immunology</i> , 2005, 15, 173-177.	0.6	7
144	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. <i>British Journal of Haematology</i> , 2003, 120, 405-412.	1.2	27

#	ARTICLE	IF	CITATIONS
145	Differences in Transplant-Related Complications between Hematologic Malignancies and Solid Tumors Receiving High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation. Tumori, 2003, 89, 385-390.	0.6	6
146	Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori, 2003, 89, 385-90.	0.6	2
147	High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability. Tumori, 2003, 89, 492-6.	0.6	0
148	Systemic aspergillosis in a patient with non-Hodgkin's lymphoma developing acute graft-versus-host disease after autologous peripheral blood stem cell transplantation. Haematologica, 2002, 87, ECR22.	1.7	2
149	Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica, 2002, 87, 1192-9.	1.7	34
150	Basiliximab for the treatment of graft rejection in haploidentical peripheral blood stem cell transplantation. Haematologica, 2002, 87, ECR44.	1.7	0
151	Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Bone Marrow Transplantation, 2001, 28, 883-888.	1.3	8
152	Graft-versus-lymphoma effect in a patient with a refractory low-grade lymphoma. Haematologica, 1999, 84, 1156-7.	1.7	0
153	Technical note: Chromosomal and mtDNA analysis of Oliver. , 1998, 105, 395-403.		2
154	HIGH-DOSE ETOPOSIDE ENABLES THE COLLECTION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WHO FAILED CYCLOPHOSPHAMIDE-INDUCED MOBILIZATION. British Journal of Haematology, 1998, 100, 612-613.	1.2	5
155	Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica, 1996, 81, 59-61.	1.7	52
156	Two consecutive courses of rh-G-CSF-mobilized peripheral blood stem cells for primary marrow alloengraftment failure: case report. Haematologica, 1996, 81, 464-7.	1.7	0
157	Thrombotic thrombocytopenic purpura: a rare late complication of allogeneic bone marrow transplantation. Haematologica, 1994, 79, 371-3.	1.7	3